



UNIVERSITY OF GOTHENBURG

Gothenburg University Publications

Trends in mortality after first hospitalization with Atrial Fibrillation diagnosis in Sweden 1987 to 2006

This is an author produced version of a paper published in:

International Journal of Cardiology (ISSN: 0167-5273)

Citation for the published paper:

Olsson, L. ; Swedberg, K. ; Lappas, G. (2013) "Trends in mortality after first hospitalization with Atrial Fibrillation diagnosis in Sweden 1987 to 2006". International Journal of Cardiology, vol. 170(1), pp. 75-80.

<http://dx.doi.org/10.1016/j.ijcard.2013.10.028>

Downloaded from: <http://gup.ub.gu.se/publication/189120>

Notice: This paper has been peer reviewed but does not include the final publisher proof-corrections or pagination. When citing this work, please refer to the original publication.

Trends in mortality after first hospitalization with Atrial Fibrillation diagnosis in Sweden 1987 to 2006

Olsson LG^{1,2}, Swedberg K², Lappas G², Stewart S³, Rosengren A².

¹ Department of Medicine, Mora Hospital, Mora, Sweden

² Department of Molecular and Clinical Medicine, Sahlgrenska Academy

University of Gothenburg, Sweden

³ NHMRC Centre of Research Excellence to Reduce Inequality in Heart Disease Baker

IDI Heart and Diabetes Institute, Melbourne, Australia

Corresponding author: Lars G Olsson

Address for correspondence: Department of Medicine, Sahlgrenska University Hospital/Östra, SE-416 85 Göteborg, Sweden. Telephone +46/31/3434086. E-mail:

larsgustavo@hotmail.com

Funding

This study was supported by Landstinget Dalarna, the Swedish Heart and Lung Foundation, the Swedish Research Council and the Swedish Council for Working Life and Social Research. SS is supported by the National Health & Medical Research Council of Australia.

Conflicts of interest

None to declare.

Keywords: Atrial fibrillation * Mortality * Epidemiology

Abstract:

Background: To examine trends in 3-year mortality after a first hospitalization with diagnosed atrial fibrillation in a large cohort with and without important comorbidities.

Methods: The Swedish Hospital Discharge and Cause of Death Registries were linked to investigate trends in mortality for all patients 35 to 84 years hospitalized for the first time with a discharge diagnosis (principal or contributory) of atrial fibrillation in Sweden during 1987 to 2006. We performed an analysis of temporal trends in mortality stratified for presence or absence of co-morbidities affecting survival.

Results: Exactly 376000 patients (56 % male, mean age 72 years) with a first diagnosis of atrial fibrillation during 1987-2006 were identified and followed for 3 years. Patients with one or more of the prespecified comorbidities had the highest mortality and the largest absolute decline in mortality, but patients without these comorbidities had a slightly larger relative decline (absolute risk reduction in 3-year mortality (AAR) from 42.5 to 34.7%, Hazard Ratio (HR) 0.76; 95% confidence interval (95% CI) 0.74 to 0.77 versus ARR 16.2% to 11.7%, HR 0.71; 0.68 to 0.74. In patients aged below 65 years, with no comorbidities, there was minimal change in mortality, and they still had a 2 times increased mortality compared to the general population (SMR 2.00; 1.90 - 2.10).

Conclusions: Survival after a first hospitalization with a diagnosis of atrial fibrillation improved regardless comorbidities. Patients aged < 65 years old without diagnosed comorbidities still had a poor prognosis compared to the general population.

Introduction

Atrial fibrillation is the most common sustained arrhythmia and represents an increasing public health challenge with profound social and economic implications (1). Recent studies have shown an increased incidence and prevalence in western Europe and the US(2-6), and the prevalence is expected to rise in the foreseeable future. Atrial fibrillation is associated with an increased risk of premature mortality. Despite an increased number of deaths associated with incident and prevalent atrial fibrillation the case-fatality has decreased during the 80s and 90s in Europe (2, 7), but not in the US(8, 9). Atrial fibrillation is associated with comorbidities such as ischemic heart disease(10), chronic heart failure(11) and stroke(12, 13). All these conditions adversely affects prognosis and have shown a general, albeit non-uniform, decline in mortality during the last 30 years(14-18). Earlier studies have performed analyses adjusted for comorbidities and/or mortality rates in the general population or within the study cohort, but this approach gives little information regarding risks in different age groups and with different sets of comorbidities.

Objectives:

We examined the risk for all-cause mortality up to three years after a first atrial fibrillation diagnosis, with respect to trends over time and further, to which extent age, gender and co-morbidities were associated with prognosis. We utilized the Swedish hospital discharge registry together with cause-specific Death register.

Design:

Setting:

Sweden has a universal health care system that provides health care (including hospital care) to the Swedish population (population ranging from 8.4 to 9.0 million people during the period 1987 to 2006). Registration of principal and contributory discharge diagnoses for all patients is mandatory in the hospital discharge register. Diagnosis at discharge is coded with the International Classification of Diseases (ICD) system (ICD 8th revision until 1986, ICD 9th revision until 1996, ICD 10th revision thereafter). Each patient is given a principal diagnosis and up to five secondary diagnoses.

For the purpose of the present study, data from the national hospital discharge and cause-specific death registers were linked through the personal identification number (PIN), which is unique for all Swedish citizens. The hospital discharge register has been in existence since the 1960s and operating on a nationwide basis, with near-complete coverage, since 1987.

Subjects:

We identified all first hospital admissions with a principal or secondary discharge diagnosis of atrial fibrillation in men and women aged 35 to 84 years during the period 1987 to 2006. The discharge codes applied were 427.93 (ICD-8) (only used for exclusion of patients with AF before 1987), 427D (ICD-9), and I48 (ICD 10). To ascertain freedom from earlier hospitalizations and to ensure that patients from all years had the same chance of being identified as a new case we censored for hospitalizations with an atrial fibrillation diagnosis up to seven years before the index hospitalization. Significant comorbidities during the preceding 7 years and including the index hospitalization were recorded. Patients who died during index hospitalization were excluded. Complete follow-up data were available from 1st January 1987 through 31st December 2007. Only patients with the possibility of experiencing 3-year survival within the observation period were included in the survival analysis.

Validity of the registers

In the period from 1987 to 1996, a primary discharge diagnosis was lacking in 0.8% of all admissions to Swedish departments of internal medicine (including admissions for cardiovascular reasons)(19). Register-based data diagnoses for heart failure and acute myocardial infarction in Sweden according to the hospital discharge register have been shown to have good validity (20, 21). In a random sample of 100 randomly selected patients with a hospital diagnosis of AF enrolled in the Malmö Diet and Cancer Study, 95 were verified by ECG while 2 probably had AF (ECG missing) yielding a 97% positive predictive value (22).

Statistical analysis

All analyses were carried out using the Statistical Analysis System (SAS), version 9.2, and the R statistical computing system, version 2.10.0. Means and proportions for continuous and categorical variables were calculated. We performed a co-variable adjusted analysis with all (relevant) comorbidities, age, gender and time periods (1987-1991; 1992-1996; 1997-2001 and 2002-2004) in order to extract comorbidities associated with an increased mortality. The independent association of each period of AF admission, age, gender and comorbidity with death was quantified as hazard ratios estimated through Cox regression.

We examined sex- and age-specified all-cause mortality from day 1 up to 1095 days (3 years) after hospital admission by time period and presence or absence of significant comorbidities. We stratified by age with 65 years as the cut-off point because we wished to characterize a relatively young population (the conventional retirement age in Sweden is 65 years) while at the same time retaining reasonable statistical power. Also, several stroke prediction scores uses 65 years as an age cutoff-point (23, 24). Cumulative incidence functions for death are presented graphically for each period. Mortality rates from the Swedish population were applied to the patient's evaluated person-years of exposed to risk to estimate the expected number of deaths and presented in a standardized mortality ratio (SMR).

The discharge codes used to define ischemic heart disease were 410-414 (ICD-8 and ICD-9), I20-I25 (ICD-10), chronic heart failure 427.00 (ICD-8), 428A, 428B, 428X (ICD-9) and I50 (ICD-10), stroke 430-434, 436 (ICD8 and ICD9) and I60-I64 (ICD10) for both ischemic and hemorrhagic strokes. Other co-morbidities were defined by the following discharge codes prior to and including the index hospitalization: diabetes: 250 (ICD-8 and ICD-9), E10, E11, E14 (ICD-10); hypertension: 401-405 (ICD-8 and 9), I10-I15 (ICD-10); valvular disease: 394-396, 424 (ICD-8 and 9), I05-I09, I34-I35 (ICD-10); hyperthyreosis: 242 (ICD-8 and ICD-9), E05 (ICD10); chronic obstructive pulmonary disease 490-492 (ICD8 and ICD-9)J40-44 (ICD-10), asthma 493 (ICD-8 and ICD-9), J45 (ICD-10) and chronic kidney disease 585-586 (ICD-8 and ICD-9), N18 and N19 (ICD10)

Results

Baseline variables

The baseline variables are presented in **table 1**. Exactly 376000 patients were discharged with a first-time diagnosis of atrial fibrillation between 1987 and 2006, 56% were men. Women were older than men (74.4 vs 70.4 years). Chronic heart failure and ischemic heart disease were the most common comorbidities, present in 27.9 and 27.8% of the patients, respectively. Overall, 14.6 % had a previous stroke diagnosis and 12.3 % diabetes mellitus. Proportionately more women had previous stroke, diagnosed hypertension and hyperthyroidism, while more men had ischemic heart disease. Equivalent proportions of men and women had concurrent chronic heart failure, diabetes, cancer, pulmonary disease (chronic obstructive pulmonary disease and asthma) and chronic kidney disease.

Predictors of mortality in multivariable analysis

Of the 328907 patients included up until 31st December 2004 thus having a possibility for a 3-year survival within the observation period, a total of 90835 patients (27.6%) died, 15.6% men and 12.0% women. **Table 2** shows the results of the co-variable-adjusted analysis of 3-year mortality. Chronic heart failure, previous stroke, diabetes mellitus, ischemic heart disease, cancer, pulmonary disease, chronic kidney disease and valvular disease were all independent predictors of all-cause mortality and all subsequent analyses were stratified according to the presence or absence of any of these comorbidities. Patients hospitalized during periods after 1987-91 had successively reduced mortality, with 3-year mortality for those hospitalized in 2002-04 30% lower than those hospitalized in the first period.

Survival trends

Figure 1 shows time trends in mortality. There was a decline in mortality during the observation period, regardless of patient category. The decline was more pronounced in the first three periods and slowed down between period 3 and 4. Patients with one or more of the pre-specified co-morbidities had the highest mortality and the largest absolute decline in mortality. However patients without any of the pre-specified comorbidities had a larger relative decline in mortality during the observation period

(absolute risk reduction in 3-year mortality (AAR) from 42.5 to 34.7%, hazard ratio (HR) 0.76; 95% confidence interval (95% CI) 0.74 to 0.77 versus ARR 16.2% to 11.7%, HR 0.71; 0.68 to 0.74 (**fig 1**). Patients with pre-specified comorbidities had an early steep increase in mortality. Patients without pre-specified comorbidities had smaller early increase in mortality and more evenly distributed events.

Age and sex-specific survival trends

Table 3 and 4 demonstrates survival trends by age, sex and comorbidity. Older patients with comorbidities experienced declines in mortality, regardless of gender (HR 0.74; 0.73 – 0.76 and HR 0.79; 0.77 – 0.82, respectively). Men 35-64 years old had a 34% reduction in 3-year mortality rates after hospital discharge (HR 0.66; 0.61 – 0.72) while young women had a virtually unchanged mortality rate. Initially higher mortality rates among younger men with comorbidities became more similar to the death rates in young women during 2002-04 while women retained their survival advantage in the older age group. In patients without any of the pre-specified comorbidities older men and women experienced significantly decreased mortality rates (HR 0.68; 0.64 - 0.73 and HR 0.73; 0.69 – 0.78, respectively). Among patients aged 35-64 year men showed a small decline in mortality with a slightly larger one for women (HR 0.82; 0.70 - 0.96 and HR 0.51; 0.37 – 0.70, respectively). Death rates in younger patients were, however, very low thus impacting on the definitive accuracy of survival estimates.

Comparison with underlying population mortality rate

Atrial fibrillation was associated with increased risk of mortality, when compared to the underlying population mortality rate (**table 5**). Because comparisons over time are subject to variation due to population trends in mortality and therefore less meaningful to report we here present the average standardised mortality ratios (SMR's) for the entire period.

Young patients with comorbidities had an almost 9-fold increased mortality compared to the general population (SMR 8.88; 8.64 – 9.13). However, despite the much lower absolute mortality in young AF patients without comorbidities, they still had a 2 times increased mortality compared to the general population (1.95; 1.84 – 2.06). Patients 65-84 years old with comorbidities had a 3-fold increased risk of mortality (3.38; 3.35 – 3.40), and those without comorbidities a 36% increased risk (1.36; 1.33 – 1.38).

Discussion:

In this large cohort of patients discharged from hospital with a first AF diagnosis during an 18-year period we found an overall decline in 3-year mortality rates, regardless of diagnosed comorbidities. This was most evident in older patients overall and young male patients with any of the pre-specified comorbidities. Young women showed, regardless of comorbidity, no certain decline in mortality rates. Regardless of presence or absence of pre-specified comorbidities, patients with an AF diagnosis had an adverse prognosis compared with the general population. This was especially evident in the younger patients.

Earlier studies on trends in mortality after “first ever” atrial fibrillation with observation periods during the 80s and the 90s have showed divergent results. Two European analyses from the Danish and Scottish hospital discharge registries have shown declines in mortality over 8 and 20-year observation periods, respectively (2, 7). Two American studies, one from Olmsted county and one from the Medicare 5% cohort showed virtually unchanged mortality rates during 15 and 20-year follow-up, with or without adjustments for mortality rates in the general study population(8, 9). There might be several reasons for these differences. Both American studies included more women than the European studies. As opposed to the present analysis several of the studies had higher overall mortality for women, and both the European studies had, as with our cohort, smaller declines in mortality over time in women than in men. The Medicare 5% sample study included older patients that were more ill than ours and the other European studies. Olmsted County study comprised of a relatively small and heterogeneous sample and may thus have a lack of statistical power compared with the other studies.

The main differences between our study and the earlier hospital registry studies are the more contemporary study period and the fact that we stratified for age and comorbidity. This approach allowed us to make some important observations. First, the poor prognosis associated with atrial fibrillation persists even in the absence of important comorbidities, especially in younger patients. Secondly, we observed significant declines in mortality in both patients with and without significant co-morbidities. The trends in

the two groups were similar, but with very different patient populations the reason for the changes may differ. In general, treatment for patients with AF has improved during the last 30 years with more patients receiving oral anticoagulants and a transition from rhythm-regulating to rate-regulating drugs, a trend started in the early 90s (25). Moreover, many of the important comorbidities have shown prognostic improvements during this time-period (16, 17, 18, 23). Thus, the decline in mortality seen in patients with comorbidities is probably due to a combination of these two trends. The reasons for the marked declines in elderly patients without any of the pre-specified comorbidities are less clear. While the use of oral anticoagulants probably also have increased in this group of patients, there may be improvements in diagnosis and treatment of comorbidities not fully reflected in the present analysis. Hypertension is the most important treatable cardiovascular risk factor and an important risk factor for ischemic heart disease, stroke (26), and chronic heart failure (27, 28), especially in conjunction with atrial fibrillation. While the prevalence of hypertension were equally low in the other hospital registries (2, 6), the prevalence ranged between 70 and 84% in the analysis from Olmsted County and 50% in the Stockholm Cohort of Atrial Fibrillation (SCAF) study (8, 29), so hypertension is most likely underreported in this cohort and its prognostic importance may be underestimated. Thirdly, as already mentioned, as opposed to both the American (8, 9), the Danish (2) and the Scottish studies (6, 7), women in the present study had lower overall mortality rates, but smaller improvements in prognosis in general than men. This was most notable in younger women with any of the prespecified comorbidities. The reasons for this are unclear. This could be influenced by the mortality trends seen in patients with myocardial infarction, angina pectoris or a chronic heart failure diagnosis (15-17, 30), or, probably less important, in patients with stroke after AF diagnosis (18), all diagnoses where women had smaller mortality reductions over time than did men. Women with heart failure more often have preserved systolic function, a syndrome with lower mortality overall but equal risk in the acute setting and with poorer treatment results (11, 31).

In younger patients without important comorbidities, males and females had similar mortality rates with no clinically important changes in risk over time. The high risk compared with age and sex-matched population is probably due to the nature of this data, an unselected hospital cohort where we could stratify by the presence or absence of

diagnosed disorders with major impact on survival, but were unable to define a subpopulation with “true” lone AF. Despite a low probability for ischemic stroke in terms of diagnosed risk factors in this age group the patients may still be at risk and AF-related strokes are particularly malignant in the young. A growing body of evidence suggests that a more widespread use of oral anticoagulants may be beneficial, even in patients with risk levels for stroke earlier considered as low (32).

The prevalence of diagnosed valvular heart disease and chronic renal disease were also remarkably low compared with more well defined cohorts. As is the case with hypertension, both conditions are probably present but not accounted for in many patients with other diagnoses such as chronic heart failure and nephropatic diabetes mellitus.

In both groups the decline in mortality was less marked during the last two time periods. There are several possible reasons for this. First, this may in part mirror the trends seen in important comorbidities, such as chronic heart failure (17). Second, as mentioned before, the paradigm shift that transformed atrial fibrillation treatment began in the early 90s (25). The initial decline and then more modest change in mortality may be due to an initially increased utilization of oral anticoagulants that successively levelled off. Indeed, the use of oral anticoagulants has increased, but several studies still indicate their under-utilization (32).

Limitations

The main strength of this analysis is the completeness of the data, with a nationwide unselected cohort of patients, and a large number of events that allowed detailed analyses by diagnosis, time period, gender and age group. Even so, these data were collected for administrative rather than research purposes and our diagnoses were not formally validated other than in small samples performed by another centres (19-22). However, given the high positive predicted value produced by the aforementioned study and two others from Denmark (99% positive predictive value in 174 patients and 92.6% positive predictive value for the AF or AFL diagnosis in 278 patients) (18, 33) we feel confident that only a minority of the patients in our study was misdiagnosed. As already mentioned, there is a probable underreporting of several important co-morbidities, most notably hypertension but also valvular heart disease and chronic renal disease and no information

is given about any disease severity. The true prognostic impact of co-morbidities in this context is therefore uncertain. Many patients with atrial fibrillation are diagnosed and treated entirely in primary care and most hospitals in Sweden perform acute or elective cardioversion on an outpatient basis only. The patients included in our analyses are thus most probably sicker than the total patient population with atrial fibrillation.

Changes in coding practices during the study may have occurred, due to an increased interest in atrial fibrillation and its risk factors or economic incentives, which may affect our results. Also, we did not have access to information on medical therapy in these patients. As already mentioned, atrial fibrillation-specific treatment has changed during the last 30 years with a marked reduction of the use of class I rhythm-regulating drugs and the increased use of OAC, together with treatment of associated conditions, the impact of these changes is unknown to us (25).

Conclusion

This analysis shows a decline in mortality rates in patients discharged from hospital with a first-time diagnosis of atrial fibrillation. The declines may be both due to changes in important comorbidities and due to atrial fibrillation-specific factors. However, atrial fibrillation is associated with a high risk of premature mortality, especially in younger patients compared with the general population. Young women had no certain improvement in prognosis over the observation period. More effort must be put into identifying adverse prognostic factors in order to reduce the high mortality rates in patients with atrial fibrillation, with or without associated comorbidities.

Acknowledgements

The authors acknowledge the EPC Swedish Board of Health and Welfare which provided all data used.

References

1. Ball J, Carrington MJ, McMurray JJ, Stewart S. Atrial fibrillation: Profile and burden of an evolving epidemic in the 21st century. *International Journal of Cardiology*. 2013 Feb 1. pii: S0167-5273(13)00004-1. doi: 10.1016. [Epub ahead of print]

2. Frost L, Vestergaard P, Mosekilde L, Mortensen LS. Trends in incidence and mortality in the hospital diagnosis of atrial fibrillation or flutter in Denmark, 1980-1999. *Int J Cardiol.* 2005 Aug 3;103(1):78-84.
3. Wolf PA, Benjamin EJ, Belanger AJ, Kannel WB, Levy D, D'Agostino RB. Secular trends in the prevalence of atrial fibrillation: The Framingham Study. *Am Heart J.* 1996 Apr;131(4):790-5.
4. Miyasaka Y, Barnes ME, Gersh BJ et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. *Circulation.* 2006 Jul 11;114(2):119-25.
5. Majeed A, Moser K, Carroll K. Trends in the prevalence and management of atrial fibrillation in general practice in England and Wales, 1994-1998: analysis of data from the general practice research database. *Heart.* 2001 Sep;86(3):284-8.
6. Stewart S, MacIntyre K, MacLeod MM, Bailey AE, Capewell S, McMurray JJ. Trends in hospital activity, morbidity and case fatality related to atrial fibrillation in Scotland, 1986--1996. *Eur Heart J.* 2001 Apr;22(8):693-701.
7. Stewart S, MacIntyre K, Chalmers JW et al. Trends in case-fatality in 22968 patients admitted for the first time with atrial fibrillation in Scotland, 1986-1995. *Int J Cardiol.* 2002 Mar;82(3):229-36.
8. Miyasaka Y, Barnes ME, Bailey KR et al. Mortality trends in patients diagnosed with first atrial fibrillation: a 21-year community-based study. *J Am Coll Cardiol.* 2007 Mar 6;49(9):986-92.
9. Piccini JP, Hammill BG, Sinner MF et al. Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries, 1993-2007. *Circ Cardiovasc Qual Outcomes.* 2012 Jan;5(1):85-93.
10. Schmitt J, Duray G, Gersh BJ, Hohnloser SH. Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. *Eur Heart J.* 2009 May;30(9):1038-45.
11. Meta-analysis Global Group in Chronic Heart Failure (**MAGGIC**). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. *Eur Heart J.* 2012 Jul;33(14):1750-7.
12. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. *Stroke.* 1991 Aug;22(8):983-8.
13. Harmsen P, Lappas G, Rosengren A, Wilhelmsen L. Long-term risk factors for stroke: twenty-eight years of follow-up of 7457 middle-aged men in Goteborg, Sweden. *Stroke.* 2006 Jul;37(7):1663-7.
14. Jhund PS, Macintyre K, Simpson CR et al. Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people. *Circulation.* 2009 Feb 3;119(4):515-23.
15. Ford ES, Ajani UA, Croft JB et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. *N Engl J Med.* 2007 Jun 7;356(23):2388-98.
16. Dudas K, Lappas G, Rosengren A. Long-term prognosis after hospital admission for acute myocardial infarction from 1987 to 2006. *Int J Cardiol.* 2012 Mar 22;155(3):400-5.
17. Shafazand M, Schaufelberger M, Lappas G, Swedberg K, Rosengren A. Survival trends in men and women with heart failure of ischaemic and non-ischaemic origin: data for the period 1987-2003 from the Swedish Hospital Discharge Registry. *Eur Heart J.* 2009 Mar;30(6):671-8.
18. Frost L, Andersen LV, Vestergaard P, Husted S, Mortensen LS. Trend in mortality after stroke with atrial fibrillation. *Am J Med.* 2007 Jan;120(1):47-53.
19. Rosen M, Alfredsson L, Hammar N, Kahan T, Spetz CL, Ysberg AS. Attack rate, mortality and case fatality for acute myocardial infarction in Sweden during 1987-95. Results from the national AMI register in Sweden. *J Intern Med.* 2000 Aug;248(2):159-64.

20. Hammar N, Alfredsson L, Rosen M, Spetz CL, Kahan T, Ysberg AS. A national record linkage to study acute myocardial infarction incidence and case fatality in Sweden. *International journal of epidemiology*. [Comparative Study Research Support, Non-U.S. Gov't]. 2001 Oct;30 Suppl 1:S30-4.
21. Ingelsson E, Arnlov J, Sundstrom J, Lind L. The validity of a diagnosis of heart failure in a hospital discharge register. *European journal of heart failure*. [Research Support, Non-U.S. Gov't Validation Studies]. 2005 Aug;7(5):787-91.
22. Smith JG, Platonov PG, Hedblad B, Engstrom G, Melander O. Atrial fibrillation in the Malmo Diet and Cancer study: a study of occurrence, risk factors and diagnostic validity. *Eur J Epidemiol*. 2010;25(2):95-102.
23. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. *Chest*. 2010;137(2):263- 272.
24. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: The Euro Heart Survey. *Chest*. 2010;
25. Hansen ML, Gadsboll N, Gislason GH, Abildstrom SZ, Schramm TK, Folke F, et al. Atrial fibrillation pharmacotherapy after hospital discharge between 1995 and 2004: a shift towards beta-blockers. *Europace*. 2008 Apr;10(4):395-402.
26. Olsson LG, Swedberg K, Lappas G, Stewart S, Rosengren A. Trends in stroke incidence after hospitalization for atrial fibrillation in Sweden 1987 to 2006. *Int J Cardiol*. 2012 Mar 29.
27. Wachtell K, Hornestam B, Lehto M, Slotwiner DJ, Gerdtts E, Olsen MH, et al. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. *J Am Coll Cardiol*. 2005 Mar 1;45(5):705-11.
28. Haywood LJ, Ford CE, Crow RS, Davis BR, Massie BM, Einhorn PT, et al. Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). *J Am Coll Cardiol*. 2009 Nov 24;54(22):2023-31.
29. Friberg L, Hammar N, Ringh M, Pettersson H, Rosengqvist M. [Stroke prophylaxis in atrial fibrillation: who gets it and who does not? Report from the Stockholm Cohort-study on Atrial Fibrillation \(SCAF-study\)](#). *Eur Heart J*; 2006; 27 (16): 1954-64.
30. Fagring AJ, Lappas G, Kjellgren KI, Welin C, Manhem K, Rosengren A. Twenty-year trends in incidence and 1-year mortality in Swedish patients hospitalised with non-AMI chest pain. Data from 1987-2006 from the Swedish hospital and death registries. *Heart*. 2010;96(13):1043-9.
31. Parkash R, Maisel WH, Toca FM, Stevenson WG. Atrial fibrillation in heart failure: high mortality risk even if ventricular function is preserved. *Am Heart J*. 2005 Oct;150(4):701-6.
32. Friberg L, Rosengqvist M, Lip GY. Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. *Circulation*. 2012; 15;(19):2298-307
33. Rix TA, Riahi S, Overvad K, Lundbye-Christensen S, Schmidt EB, Joensen AM. Validity of the diagnoses atrial fibrillation and atrial flutter in a Danish patient registry. *Scand Cardiovasc J*. 2012;46(3):149-53.

Figure legends:

Figure 1. Temporal trends in mortality up to three years after hospital discharge with “first-ever” atrial fibrillation diagnosis

Solid lines: Patients without the prespecified comorbidities.

Dashed lines: Patients with the prespecified comorbidities

Mortality




Table 1. Baseline characteristics for patients with a first hospital diagnosis of atrial fibrillation in Sweden 1987 to 2006

	<i>Men</i>	<i>Women</i>	<i>All</i>
Number of patients	210696	165304	376000
Mean age (SD)	70.4 (10.3)	74.4 (8.3)	72.1 (9.7)
Medical history (including index admission)			
Previous stroke n (%)¹	29199 (13.9)	25523 (15.4)	54722 (14.6)
Chronic Heart Failure n (%)	46395 (28.1)	58539 (27.8)	104934 (27.9)
Ischemic Heart Disease n (%)	64000 (30.4)	40604 (24.6)	104604 (27.8)
Diabetes mellitus n (%)	26013 (12,3)	20418 (12,4)	46431 (12,3)
Valvular disease n (%)	13677(6.5)	11755(7.1)	25432(6.8)
Hypertension n (%)	41939 (19.9)	38138 (23.1)	80077 (21.3)
Chronic Kidney Disease n (%)	2487 (1.2)	1423 (0.9)	3910 (1.0)
Hyperthyreosis n (%)	897 (0.4)	2695 (1.6)	3592 (1.0)
Pulmonary disease n (%)²	14507 (6.9)	11166(6.8)	25673 (6.8)
Cancer n (%)	25554 (12.1)	20297 (12.3)	45851 (12.2)

1. Includes stroke at hospital admission
2. Includes asthma and chronic obstructive pulmonary disease

Table 2. Multivariable analysis of risk for 3-year mortality in 328907 patients with a first hospital diagnosis of atrial fibrillation in Sweden 1987 to 2004.

<i>Variables</i>	<i>Hazard Ratio</i>	<i>95% Confidence Interval</i>
1987-1991	1 (reference)	
1992-1996	0.83	0.82 - 0.85
1997-2001	0.72	0.71 - 0.74
2002-2004	0.68	0.67 - 0.69
Female sex	0.80	0.79 - 0.81
Age at discharge (per decade increase)	1.89	1.88 - 1.91
Cancer	2.07	2.04 - 2.10
Chronic heart failure	1.72	1.70 - 1.74

Previous stroke	1.66	1.64 - 1.69
Diabetes mellitus	1.48	1.45 - 1.50
Chronic kidney disease	2.49	2.39 - 2.58
Pulmonary disease²	1.50	1.47 - 1.53
Ischemic heart disease	1.16	1.14 - 1.17
Valvular heart disease	1.10	1.07 - 1.12
Hypertension	0.94	0.93 - 0.96
Hyperthyreosis¹	0.91	0.85 - 0.97
All p-values <0.0001 except 1. p=0.0044 2. Includes Asthma and Chronic Obstructive Pulmonary Disease		

Table 3. Temporal trends in mortality up to three years after first hospitalisation with a first atrial fibrillation diagnosis. Patients with prespecified diagnoses

	<i>n</i> <i>deaths</i>	<i>Mortality</i> <i>rate/1000</i>	<i>Hazard</i> <i>Ratio</i>	<i>95% CI</i>	<i>p-value</i>	<i>n</i> <i>deaths</i>	<i>Mortality</i> <i>rate/1000</i>	<i>Hazard</i> <i>Ratio</i>	<i>95% CI</i>	<i>p-</i> <i>value</i>
35-64		Males					Females			
1987-1991	1000	94.3	1			277	67.5	1		
1992-1996	1050	75.1	0.80	0.74- 0.88	<.0001	417	74.9	1.10	0.95 - 1.29	0.20
1997-2001	1052	65.0	0.70	0.64- 0.76	<.0001	401	65.8	0.97	0.84 - 1.14	0.74
2002-2004	475	60.4	0.66	0.61- 0.72	<.0001	169	61.2	0.91	0.78 - 1.05	0.20
65-84										
1987-1991	9954	232.3	1			8171	197.4	1		
1992-1996	13071	201.2	0.88	0.85- 0.90	<.0001	10379	175.7	0.90	0.87-0.92	<.0001
1997-2001	11962	177.9	0.78	0.76- 0.80	<.0001	9304	155.9	0.80	0.78-0.83	<.0001
2002-2004	5046	172.8	0.74	0.73- 0.76	<.0001	3872	154.7	0.79	0.77-0.82	<.0001



Table 4. Temporal trends in mortality up to three years after first hospitalisation with a first atrial fibrillation diagnosis. Patients with no prespecified diagnoses

	<i>n</i> <i>deaths</i>	<i>Mortality</i> <i>rate/1000</i>	<i>Hazard</i> <i>Ratio</i>	<i>95% CI</i>	<i>p-value</i>	<i>n deaths</i>	<i>Mortality</i> <i>rate/1000</i>	<i>Hazard</i> <i>Ratio</i>	<i>95% CI</i>	<i>p-value</i>
35-64		Males					Females			
1987-1991	261	16.6	1			80	13.6	1		
1992-1996	288	15.2	0.92	0.78-1.09	0.32	69	9.3	0.68	0.49-0.94	0.02
1997-2001	294	12.3	0.74	0.63-0.87	0.0004	101	11.2	0.82	0.61-1.10	0.19
2002-2004	130	12.0	0.82	0.70-0.96	0.014	30	7.4	0.51	0.37-0.70	<.0001
65-84										
1987-1991	1742	91.9	1			1676	74.1	1		
1992-1996	1986	76.0	0.83	0.78-0.88	<.0001	1872	62.7	0.85	0.79 - 0.90	<.0001
1997-2001	2113	67.3	0.74	0.69-0.78	<.0001	1915	55.2	0.75	0.70 - 0.80	<.0001
2002-2004	876	63.4	0.68	0.64-0.73	<.0001	802	54.3	0.73	0.69 - 0.78	<.0001

Table 5. Standardised mortality ratios in patients hospitalized with AF in 1987-2004 by age group and presence or absence of comorbidities

<i>Age group</i>	<i>With comorbidities</i>			<i>Without comorbidities</i>		
	<i>Observed deaths</i>	<i>Expected deaths</i>	<i>SMR; 95% CI</i>	<i>Observed deaths</i>	<i>Expected deaths</i>	<i>SMR; 95% CI</i>
35-64	4841	547.0	8.87; 8.63 – 9.13	1253	632.3	1.95; 1.84 – 2.06
65-84	71759	21210.8	3.38; 3.35 – 3.40	13542	9374.1	1.36; 1.33 – 1.38

